Neuroscience Week 2: Neurotransmitters Flashcards
Classes of Neurotransmitters
6 listed
- Acetylcholine
- Biogenic Amines
- Amino Acids
- Peptides
- Purines
- Gases and Lipids
Direct Neurotransmitters
Bind to ion channels and open them
Indirect Neurotransmitters
signal through second messenger pathways (G-protein)
Biogenic Amines Examples
Dopamine
Serotonin
Neurotransmitters: Amino Acid examples
GABA
Glutamate
Glycine
Neurotransmitters: Peptides examples
Endorphins
Substance P
Neurotransmitters: Purines examples
ATP
Adenosine
Neurotransmitters: Gases and Lipids examples
Nitric oxide
Endocannabinoids
Identify


Anterograde transport is in which direction
Away from the cell body
Retrograde transport is in which direction
Toward the cell body
Anterograde and retrograde transport speeds

Anterograde and retrograde transport Caveats

Some acetylcholinesterase inhibitors
- Pyridostigmine (M. Gravis)
- Donepezil (Alzheimer’s)
Ach Neurotransmission

Nicotinic Receptors AKA
Excitatory
Muscarinic Receptors AKA
Mixed
Nicotinic Receptors Function
Cation permeable channel (ionotropic)
Nicotinic Receptors Location
- NMJ
- Autonomic ganglia
- CNS
Nicotinic Receptors Competitive Antagonist
Tubocurarine
Nicotinic Receptors Effect of ACh cholinesterase inhibition
Activation
Muscarinic Receptors Effect of ACh cholinesterase inhibition
Activation
Muscarinic Receptors Effect Competitive Antagonist
Atropine
Muscarinic Receptors Location
- Parasympathetic
- Myocardium (M<span>2</span>: G<span>i</span> coupled; ↓cAMP)
- Smooth muscle (M1: Gq coupled; ↑Ca2+)
- CNS
Muscarinic Receptor Function
G Protein-coupled receptor (metabotropic)
ACh receptor overview

Identify


Basal Nucleus of Meynert is damaged in?
Alzheimer’s Disease
Identify


Identify


Overview

Overview of Pharmacology of Neuromuscular Blocking Agents

Non-Depolarizing Competitive Antagnoists Examples
Isoquinalines:
- d-Tubocurarine
- atracurium
Steroids:
- Pancuronium
- Rocuronium
- vecuronium
Non-Depolarizing Competitive Antagnoists timing of Action
Onset 90 sec
duration 20-50 minutes
Non-Depolarizing Competitive Antagnoists elimination
Spontaneous (hydrolysis)
Kidney and/or liver
Non-Depolarizing Competitive Antagnoists Uses
Surgical relaxation
endotracheal intubation
control of ventilation (ICU)
Non-Depolarizing Competitive Antagnoists Adverse Effects
hypotension and bronchoconstriction due to histamine release
tachycardia
prolonged paralysis
Non-Depolarizing Competitive Antagnoists Reversal of blockade
cholinesterase inhibitors
Sugammedex (modified gamma-cyclodextrin-for steroid derivatives)
Non-Depolarizing Competitive Antagnoists Interactions
NMJ blockade is potentiated by volatile general anesthetics and antibiotics (aminoglycosides)
Depolarizing Agonists MOA
Phase 1: depolarizing block of Na+ channels (inactivation gate closes)
Phase 2: Desensitization (nAChR in closed state)
Depolarizing Agonists Examples
Succinylcholine
Depolarizing Agonists Timing
Onset 30 sec
duration < 8 min
Depolarizing Agonists elimination
Plasma and liver cholinesterases (insensitive to synaptic acetylcholinesterase)
Depolarizing Agonists Uses
- Surgical relaxation
- Endotracheal entubation
- Control of ventilation (ICU)
- Aid in treatment of convulsions or electroconvulsive therapy (Succinyl-Ch)
Depolarizing Agonists Adverse effects
6 listed
- Rhabdomyolysis
- myalgias
- hyperkalemia
- hypercalcemia
- ↑ intraocular pressure
- ↓ heart rate due to muscarinic effects
Depolarizing Agonists Reversal of blockade
Stop infusion (rapid elimination)
Depolarizing Agonists Interactions
Malignant hyperthermia is a rare complication when used in conjunction with volatile anesthetics
End-plate depolarizing effect can be blocked by nondepolarizing agent
Transdermal electrical stimulation

conditions that have the potential to up-regulate acetylcholine receptors
6 listed
potential for hyperkalemia with succinylcholine

conditions that have the potential to up-regulate acetylcholine receptors
6 listed
& Effects
- increased resistance to non-depolarizing
- hyperkalemia after succinylcholine

conditions that have the potential to down-regulate acetylcholine receptors
3 listed

Myasthenia Gravis Etiology

Myasthenia Gravis Age of Presentation

Myasthenia Gravis Clinical Presentation

Myasthenia Gravis Associated with

Myasthenia Gravis Laboratory Tests

Myasthenia Gravis Treatment

Lambert-Eaton Etiology

Lambert-Eaton Age of Presentation

Lambert-Eaton Clinical Presentation

Lambert-Eaton Associated with

Lambert-Eaton Laboratory Tests

Lambert-Eaton Treatment

Botulism Etiology

Botulism Age of Presentation

Botulism Clinical Presentation

Botulism Associated With

Botulism Laboratory tests

Botulism Treatment

OPMD Etiology

OPMD Age of presentation

OPMD Clinical Presentation

OPMD Associated With

OPMD Laboratory Tests

OPMD Treatment

GABA Pathway

Pyridoxine Deficiency
Pyroxidine (Vitamin B6) deficiency may occur in patients without adequate dietary intake can cause seizures
certain conditions can be risky for B6 deficiency despite adequate dietary intake include the elderly patients undergoing dialysis, patients with liver disease, and pregnant women
Some anti-epileptic drugs can modulate
GABA release
Closed loop GABA pathway is called
GABA Shunt
GABA Receptor Types
- GABAA
- GABAB
GABAA Function
anion permeable channel (ionotropic)
GABAA Location
All CNS (Glycine receptors are also anion permeable; mediated inhibition in the brain stem and spinal cord antagonized by strychnine)
GABAA Clinical Importance Diseases
- anxiety and sleep disorders
- Seizures
- Detox (alcohol withdrawal)
- Surgical conditions and critical care
GABAA Drug (potentiators)
- Anxiolytics, sedatives, hypnotics (e.g. benzodiazepines)
- Anti-convulsants (e.g. phenobarbital)
- Benzodiazepines
- General anesthetics (e.g. propofol)
GABAA Importance in other diseases
- Huntington’s Disease
- Hepatic encephalopathy
GABAA Pharmacology pneumonics
Benzodiazepines increase frequency of channel opening = frenzodiazepines
Barbituates the duration of openings = barbidurates
GABAB Function
G protein-coupled receptor (metabotropic)
GABAB Location
All CNS
GABAB Clinical Importance Diseases
- Spasticity
- Substance use disorder
GABAB Clinical Importance Drug
- Spasmolytic agents (e.g. baclofen)
- gamma-hydroxybutyric acid (GHB)
GABAB Dual Mechanism of Action
has a dual mechanism of action:
1) presynaptically, inhibit Ca2+ channels, reducing transmitter release
2) postsynaptically, potentiate K+ channels, hyperpolarizing membrane potential
Glutamate pathway

Glutamate release is modulated by some?
Anti-epileptic drugs and riluzole (used for amyotrophic lateral sclerosis)
Glutamate Receptors
- NMDA (Excitatory)
- AMPA (Excitatory)
NMDA Receptor Function
- Cation permeable channel (ionotropic)
- Ca2+ permeable (excitotoxicity)
- Requires both glutamate and glycine for activation
- Blocked by Mg2+ at negative membrane potentials
- Involved in learning and memory
NMDA Receptor Location
All CNS
NMDA Receptor Clinical Importance

AMPA Receptor Function
- Cation permeable channel (ionotropic)
- activated by glutamate alone at negative membrane potentials (excitotoxicity)
- Involved in learning and memory
AMPA Receptor Location
All CNS
AMPA Receptor Clinical importance
Epilepsy -> Perampanel (anti-convulsant)
NMDA Mg2+ Block


Postsynaptic Integration

EPSP
Excitatory post-synaptic potential depolarizes and makes an action potential more likely
IPSP
Inhibitory post-synaptic potential is inhibitory and hyperpolarizes making an action potential less likely
Synaptic potentiation
Continuous synapse use enhances stimulation
Presynaptic inhibition
Release of neurotransmitter blocked by another neuron’s axoaxonal synapse
Temporal Summation
Neuron signals close together in time
Spatial summation
multiple simultaneous stimulations at different locations
summary of neurotransmitters

Catecholamine synthesis

Serotonin and melatonin synthesis

Question 1


Question 2


Question 3


Question 4


Question 7


Question 8


Question 9


Question 10


Question 11


Question 12


Question 13


Question 14


Question 15


Question 16


Question 17


Question 18


Question 19


Question 20


Question 21


Question 22


Question 23


antagonized by strychnine
Glycine Receptors